<i>Helicobacter pylori</i> infection has a detrimental impact on the efficacy of cancer immunotherapies

Abstract

Our study unveils for the first time that the stomach microbiota affects the response to cancer immunotherapies and that <i>H. pylori</i> serology would be a powerful tool to personalize cancer immunotherapy treatment.